Damora Therapeutics, Inc.
PosiFunda Ratios Only on PositoAI
PositoAI's own ratios from Damora Therapeutics, Inc.'s yearly results (2022–2025), compared with Healthcare companies in United States. Tap ? on any ratio for what it means.
What stands out
- Debt Due Cover Ratio: Operating cash was negative last year, while some debt falls due within a year. Lower than 96% of Healthcare companies in United States.
Cash quality
Profit Cash Ratio
—Data incomplete
Self-Funding Ratio
—Data incomplete
Cash Locked Ratio
—Data incomplete
Growth quality
Steadiness Ratio
0/3 · 2/3Sales grew in 0 of the last 3 years; profit grew in 2 of 3.
Less steady than 70% of Healthcare companies in United States.
Growth Efficiency Ratio
—Data incomplete
Asset Productivity Ratio
—Data incomplete
Balance-sheet strength
Debt Due Cover Ratio
-448.4×Operating cash was negative last year, while some debt falls due within a year.
Lower than 96% of Healthcare companies in United States.
Cash Cushion Ratio
+19%Cash, after subtracting all debt, equals 19% of its market value (net cash).
Higher than 62% of Healthcare companies in United States.
Tangible Assets Ratio
—Data incomplete
Tangible Net Worth Ratio
—Data incomplete
Shareholders
Standard fundamentals
P/E, P/B, ROE, debt, growth and more (10)
Damora Therapeutics, Inc. made a loss over the last year. Damora Therapeutics, Inc. owes $0.05 for every $1 it owns. Damora Therapeutics, Inc. made a loss in each of the last two years.
Compared with Healthcare companies in United States · latest annual results Dec 2025.
P/E ratio
LossDamora Therapeutics, Inc. made a loss over the last year, so its P/E ratio is not meaningful.
P/B ratio
2.60The share price is 2.60 times Damora Therapeutics, Inc.'s book value per share, higher than 50% of Healthcare companies in United States.
Market cap
$1.3 BThe total market value of all of Damora Therapeutics, Inc.'s shares at today's price (share price × number of shares), larger than 68% of Healthcare companies in United States. PosiCap size class: Meso Cap.
Net worth (book value)
$516 MWhat Damora Therapeutics, Inc. would have left on paper if it sold everything it owns and paid everything it owes, from its latest balance sheet (30 Jun 2026).
Book value per share
$8.36Net worth divided by the number of shares. The share price of $21.71 is 2.6 times this, which is the P/B above.
Return on equity (ROE)
-99.7%Damora Therapeutics, Inc. lost 99.7% of its shareholders' money over the last year, lower than 71% of Healthcare companies in United States.
Owes vs Owns
0.05×Damora Therapeutics, Inc. owes $0.05 for every $1 it owns (low), lower than 96% of Healthcare companies in United States.
Dividend yield
NoneDamora Therapeutics, Inc. does not currently pay a dividend.
Profit growth
LossDamora Therapeutics, Inc. made a loss in each of the last two years.
Cash vs debt
Net cashDamora Therapeutics, Inc. held $258 M more cash than debt (net cash) at Dec 2025.
Questions
How is P/B calculated on PositoAI?
P/B is market cap divided by net worth from the latest balance sheet. For Damora Therapeutics, Inc.: $1.3 B ÷ $516 M (30 Jun 2026) = 2.6.
What is Damora Therapeutics, Inc.'s return on equity?
Damora Therapeutics, Inc. lost 99.7% of its shareholders' money over the last year, lower than 71% of Healthcare companies in United States.
How much does Damora Therapeutics, Inc. owe compared with what it owns?
Damora Therapeutics, Inc. owes $0.05 for every $1 it owns (low), lower than 96% of Healthcare companies in United States.
Does Damora Therapeutics, Inc. pay a dividend?
No. Damora Therapeutics, Inc. does not currently pay a dividend.
Figures from the company's yearly results and PositoAI's own data. Full tables are on the Go Deep tab. What each figure means. PositoAI is for research and education only and is not investment advice.